Increasing the diagnosis of multifocal primary breast cancer by the use of bilateral whole-breast ultrasound

Wilkinson, Louise; Given-Wilson, Rosalind; Hall, Timothy J.; Potts, Henry W W; Sharma, Anita; Smith, Ellena

doi:10.1016/j.crad.2004.10.015

Cited by 61 publications

(44 citation statements)

References 20 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Therefore, special attention should be paid to Asia-Pacific patients in the decision made on breast preservation because of their relatively small breast size, although the reported incidence of multiple tumors in the region was lower than that in the developed world either in pathological evaluations using mastectomy specimens (8.3% vs 63%) 16,24 or in clinical evaluations using USG (11% vs 34%). 25,26 In the present study, despite the limited number of patients accrued, the cosmetic result was comparable to that of unifocal disease from our institute, as reported previously. 27 Another possible factor explaining the excellent result of our study is the use of adjuvant systemic therapy.…”

Section: Discussionsupporting

confidence: 91%

Results of breast‐conserving therapy for multifocal or multicentric breast cancers

Chie

Kim²,

Han

et al. 2009

Asia-Pac J Clncl Oncology

View full text Add to dashboard Cite

Aim:To evaluate the outcome of breast-conserving treatment including adjuvant radiotherapy in patients with multifocal or multicentric breast cancers. Methods: Between February 1996 and January 2002 13 patients presented with multifocal or multicentric breast tumors underwent breast-conserving therapy. Their median age was 44 years (range; 32-56). Nine patients had T1 disease and four had T2 disease. Nodal involvement was confirmed in three patients. All patients had breast-conserving surgery and axillary lymph node dissection with clear resection margin. Whole breast irradiation was given up to 50.4 Gy in 28 fractions followed by 10 Gy boost to tumor bed. Twelve patients received adjuvant systemic therapy: chemotherapy in four patients, hormonal therapy in five patients and both in three patients. Results: At a median follow-up duration of 70 months, all patients were alive without evidence of disease. The cosmetic outcome was evaluated in 11 patients. Cosmesis was excellent in two patients, good in six patients and fair in three patients. Conclusion: Multifocal and/or multicentric breast cancers can be successfully treated with breastconserving surgery and adjuvant radiotherapy when complete microscopic resection and contemporary systemic therapy are given.

show abstract

Section: Discussionsupporting

confidence: 91%

Results of breast‐conserving therapy for multifocal or multicentric breast cancers

Chie

Kim²,

Han

et al. 2009

Asia-Pac J Clncl Oncology

View full text Add to dashboard Cite

show abstract

“…En el último tiempo, y debido al uso masivo de técnicas de imagen como ecotomografía mamaria bilateral y resonancia magnética nuclear (RMN), el cáncer de mama MFMC es más común-mente diagnosticado. Al utilizar la mamografía, el 15% de los cánceres de mama corresponden a tumores MFMC, mientras que éstos alcanzan el 34% del total al agregar un estudio ecográfico mamario bilateral 6 . Debido a la gran incidencia de esta neoplasia y al aumento indiscutible en el diagnóstico de tumores MFMC en el último tiempo, resulta importante establecer de qué manera la MFMC afecta en la sobrevida general de los pacientes con cáncer de mama, lo que no ha sido definido claramente.…”

Section: Introductionunclassified

Cánceres de mama multifocales-multicéntricos: ¿Son realmente de peor pronóstico?

C²,

R³

et al. 2009

Rev Chil Cir

View full text Add to dashboard Cite

Multifocal-multicentric breast cancers: are they of worse prognosis?The malignant mammary pathology can be presented like unifocal or multifocal-multicentric tumors (MFMC). The influence of this factor as prognostic is controversial. Objective: Establish if the presence of MFMC breast cancer, in comparison to the unifocal breast cancer, is associated to worse prognosis. Patients and Method: Combined prospective-retrospective cohort, corresponding to the totality of patients treated by surgery of breast cancer at Hospital FACH between 1972 and 2007 that fulfilled the inclusion criteria, obtaining a total of 589 patients. The statistic analysis was done with Kolmogorov-Smirnov tests and T-student for quantitative variables, chi square for qualitative variables and Kaplan-Meier curves with log rank test for survival. Results: The 93.4% of the patients had unifocal breast cancer, while the rest (6.6%) had MFMC cancer. There were no significant statistical differences between ages of both groups (57.88 and 54.92 years for unifocal and MFMC, respectively). MFMC cancer group presented more bilateral cancer than unifocal cancer group (7.7% versus 1.6%; p = 0.04); also, the lymph node affectation was greater in MFMC group (4.06 versus 1.83 lymph nodes; p = 0.001). There were no statistical significant differences in 5 years survival when comparing unifocal and MFMC tumors (81.8% and 90.4%, respectively; p = 0.223). There were no differences on 5 years free metastasis survival between both groups (Unifocals 86.2%; MFMC 75%; p = 0.651). Discussion: MFMC breast cancer was associated to bad prognostic factors, nevertheless, there was not significant differences in 5 years metastasis free survival and global survival between both groups, reason why multifocality-multicentricity would not confer worse prognosis to the disease.Key words: Breast cancer, multifocality, multicentricity, survival, prognosis. ResumenLa patología mamaria maligna puede manifestarse como tumores unifocales o multifocalesmulticéntricos (MFMC). La influencia de este factor en el pronóstico es controversial. Objetivo: Establecer si la presencia de cáncer de mama MFMC se asocia a peor pronóstico. Pacientes y Método: Cohorte combinada prospectiva-retrospectiva de 589 pacientes sometidas a cirugía por cáncer de mama en el HospiRev.

show abstract

“…As advances in preoperative imaging continue, the number of MF and MC tumors identified increases [3][4][5], and better guidelines for their management are needed. In particular, questions still exist regarding the optimal locoregional (LR) therapy for MF and MC breast cancer.…”

Section: Introductionmentioning

confidence: 99%

Breast Cancer Multifocality and Multicentricity and Locoregional Recurrence

et al. 2013

View full text Add to dashboard Cite

Background. The impact of multifocal (MF) or multicentric (MC) breast cancer on locoregional (LR) control rates is unknown. Methods. MF was defined as two or more separate invasive tumors in the same quadrant of the breast. MC was defined as two or more separate invasive tumors occupying more than one quadrant of the same breast. Patients were categorized by LR treatment: breast conservation therapy (BCT; n ϭ 256), mastectomy (n ϭ 466), or mastectomy plus postmastectomy radiation therapy (PMRT; n ϭ 184). All patients with MC disease had mastectomy (10 patients treated with BCT for MC disease were excluded). The Kaplan-Meier product limit method was used to calculate 5-year LR control rate. Cox proportional hazards models were used to determine independent associations of multifocality or multicentricity with LR control.Results. A total of 906 patients had either MF disease (n ϭ 673) or MC disease (n ϭ 233). With median follow-up of 52 months, the 5-year LR control rate was 99% for MF, 96% for MC, and 98% for unifocal tumors (p ϭ .44). Subset analysis revealed no difference in LR control regardless of the LR treatment (p ϭ .67 for BCT, p ϭ .37 for mastectomy, p ϭ .29 for mastectomy plus PMRT). There were five in-breast recurrences after BCT in the MF group. MF and MC did not have an independent impact on LR control rate on multivariate analysis. Conclusion. MF and MC disease are not independent risk factors for LR recurrence. Patients with MF and MC breast cancer had rates of LR control similar to those of their unifocal counterparts. These data suggest that BCT is a safe option for patients with MF tumors and that MF or MC disease alone is not an indication for PMRT. The Oncologist 2013;18:1167-1173 Implications for Practice: This work reviews the risk of locoregional recurrences in patients with breast cancer treated with different approaches, as currently recommended by standard guidelines. We looked at 2,816 cases with unifocal disease, 673 cases with multifocal (MF) disease, and 233 cases with multicentric (MC) disease. We showed that MF and MC breast cancers are not independently associated with increased locoregional recurrence rates and that breast conservation therapy is a safe option for patients with MF tumors. MF or MC disease alone is not an indication for postmastectomy radiation therapy.

show abstract

Increasing the diagnosis of multifocal primary breast cancer by the use of bilateral whole-breast ultrasound

Cited by 61 publications

References 20 publications

Results of breast‐conserving therapy for multifocal or multicentric breast cancers

Results of breast‐conserving therapy for multifocal or multicentric breast cancers

Cánceres de mama multifocales-multicéntricos: ¿Son realmente de peor pronóstico?

Breast Cancer Multifocality and Multicentricity and Locoregional Recurrence

Contact Info

Product

Resources

About